Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.

NCT04239469 is registered in ClinicalTrials.gov with Knop Laboratorios as lead sponsor.

NCT NCT04239469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04239469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.
Lead sponsor
Knop Laboratorios
Phase
Phase 2
Overall status
Unknown status
Start date
January 15, 2020
Completion date
September 15, 2020
Enrollment
44 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis, fibromyalgia